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The efficacy of antibiotic treatments in dairy cows at dry-off to prevent new
intramammary infections during the dry-period or clinical mastitis during
early lactation: A protocol for a systematic review
Abstract
Rationale: The majority of antibiotic use in the dairy industry is for the treatment and prevention of
intramammary infections (IMI); in the Netherlands, approximately 60 % of all antimicrobial use in dairy is for
this purpose, with two-thirds being dry cow therapy (Lam et al., 2012). In the United States, over 90 % of
dairy cows receive dry cow therapy after every lactation (USDA-APHIS, 2016), with the goal of treating or
preventing IMI during the dry period. These infections are strongly associated with risk of development of
clinical mastitis in the first two weeks post-calving, which represents the highest risk period for this disease
(Green et al., 2002). To combat this, blanket dry cow therapy (intramammary antimicrobial treatment of all
quarters of all cows after the last milking of the lactation) was recommended for decades as part of a
comprehensive strategy to reduce IMI in the dry period (Neave et al., 1969), and has been widely adopted in
North America and the United Kingdom (Ruegg, 2017). Although cow2 level selective dry cow therapy has
been in use in some regions for several decades (Schultze, 1983), interest has more recently increased
worldwide, in part driven by concern for antimicrobial use and its relationship with the development of
antimicrobial resistance between species (WHO, 2015), including nation-specific regulations (Santman-
Berends et al., 2016). Selective dry cow therapy has been employed because it is a means to rapidly reduce the
amount of antimicrobials used in dairy cattle (Vanhoudt et al., 2018), rather than because it is known to
contribute importantly to antimicrobial resistance (Oliver et al., 2011).
With a greater concern for prudent antibiotic use in the dairy industry, it is important that decision making
with regards to dry cow therapy at both the cow and herd levels be evidencebased. Choosing ineffective
antibiotics, or using antibiotic when not warranted, unnecessarily contributes to use while having little impact
on controlling disease, which has substantial bearing to both profitability and animal welfare (Leslie &
Petersson-Wolfe, 2012). Systematic reviews of randomized controlled trials yield the highest level of evidence
for efficacy of treatment under field conditions (Sargeant and O’Connor, 2014), and comparative efficacy can
be examined using network meta-analysis for multiple comparisons. Establishing the efficacy of both cow-
level antibiotic therapy and herd-level dry cow antibiotic protocols for the prevention of IMI will serve to
improve decision makers’ ability to engage in effective stewardship of antibiotics.
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Author	contributions:	
All	authors	contributed	to	the	development	of	the	review	question	and	the	methodology	
described	in	this	proposal.		HW	and	JG	developed	the	search	strategy.	JMS	drafted	the	protocol,	
with	input	and	final	approval	of	all	co-authors.	
	
Registration:		
This	protocol	is	archived	in	the	University	of	Guelph’s	institutional	repository	(The	Atrium;	
https://atrium.lib.uoguelph.ca/xmlui/handle/10214/10046)	and	published	online	with	
Systematic	Reviews	for	Animals	and	Food	(SYREAF)	available	at:		http://www.syreaf.org/.	The	
systematic	review	will	be	reported	using	the	Preferred	Reporting	Items	for	Systematic	Reviews	
and	Meta-Analyses	(PRISMA)	statement	guidelines	(Liberati	et	al.,	2009).		This	protocol	is	
reporting	using	the	items	(headings)	recommended	in	the	PRISMA-P	guidelines	(Moher	et	al.,	
2015).	
	
Support.		Funding	support	for	this	systematic	review	/	meta-analysis	/	network	meta-analysis,	
including	the	development	of	the	protocol,	was	provided	by	The	Pew	Charitable	Trusts.	
	
Introduction.	
Rationale:	The	majority	of	antibiotic	use	in	the	dairy	industry	is	for	the	treatment	and	
prevention	of	intramammary	infections	(IMI);	in	the	Netherlands,	approximately	60	%	of	all	
antimicrobial	use	in	dairy	is	for	this	purpose,	with	two-thirds	being	dry	cow	therapy	(Lam	et	al.,	
2012).	In	the	United	States,	over	90	%	of	dairy	cows	receive	dry	cow	therapy	after	every	
lactation	(USDA-APHIS,	2016),	with	the	goal	of	treating	or	preventing	IMI	during	the	dry	period.	
These	infections	are	strongly	associated	with	risk	of	development	of	clinical	mastitis	in	the	first	
two	weeks	post-calving,	which	represents	the	highest	risk	period	for	this	disease	(Green	et	al.,	
2002).	To	combat	this,	blanket	dry	cow	therapy	(intramammary	antimicrobial	treatment	of	all	
quarters	of	all	cows	after	the	last	milking	of	the	lactation)	was	recommended	for	decades	as	
part	of	a	comprehensive	strategy	to	reduce	IMI	in	the	dry	period	(Neave	et	al.,	1969),	and	has	
been	widely	adopted	in	North	America	and	the	United	Kingdom	(Ruegg,	2017).	Although	cow-
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level	selective	dry	cow	therapy	has	been	in	use	in	some	regions	for	several	decades	(Schultze,	
1983),	interest	has	more	recently	increased	worldwide,	in	part	driven	by	concern	for	
antimicrobial	use	and	its	relationship	with	the	development	of	antimicrobial	resistance	
between	species	(WHO,	2015),	including	nation-specific	regulations	(Santman-Berends	et	al.,	
2016).	Selective	dry	cow	therapy	has	been	employed	because	it	is	a	means	to	rapidly	reduce	the	
amount	of	antimicrobials	used	in	dairy	cattle	(Vanhoudt	et	al.,	2018),	rather	than	because	it	is	
known	to	contribute	importantly	to	antimicrobial	resistance	(Oliver	et	al.,	2011).	
With	a	greater	concern	for	prudent	antibiotic	use	in	the	dairy	industry,	it	is	important	that	
decision	making	with	regards	to	dry	cow	therapy	at	both	the	cow	and	herd	levels	be	evidence-
based.	Choosing	ineffective	antibiotics,	or	using	antibiotic	when	not	warranted,	unnecessarily	
contributes	to	use	while	having	little	impact	on	controlling	disease,	which	has	substantial	
bearing	to	both	profitability	and	animal	welfare	(Leslie	&	Petersson-Wolfe,	2012).	Systematic	
reviews	of	randomized	controlled	trials	yield	the	highest	level	of	evidence	for	efficacy	of	
treatment	under	field	conditions	(Sargeant	and	O’Connor,	2014),	and	comparative	efficacy	can	
be	examined	using	network	meta-analysis	for	multiple	comparisons.	Establishing	the	efficacy	of	
both	cow-level	antibiotic	therapy	and	herd-level	dry	cow	antibiotic	protocols	for	the	prevention	
of	IMI	will	serve	to	improve	decision	makers’	ability	to	engage	in	effective	stewardship	of	
antibiotics.	
Objectives:		The	objective	of	this	protocol	is	to	describe	the	methods	for	a	systematic	review	
and	network	meta-analyses	to	address	the	efficacy	of	antibiotic	dry	cow	treatments	to	prevent	
mastitis.		The	specific	review	questions	to	be	addressed	in	this	protocol	(and	the	subsequent	
review)	are	as	follows:	
1. At	the	individual	cow	level:	What	is	the	efficacy	of	antibiotic	treatments	at	dry-off	to	
prevent	new	IMI	during	the	dry-period	or	clinical	mastitis	during	the	subsequent	lactation?	
							The	specific	PICO	elements,	which	will	define	the	eligibility	criteria,	are	as	follows:	
i. Population:	Dairy	cows	after	their	first	(or	greater)	lactation	without	existing	IMI	at	
cessation	of	milking.		
ii. Intervention:	Dry-cow	interventions	containing	antibiotics	given	systemically	or	intra-
mammary	with	or	without	other	concurrent	dry	cow	treatment.	
iii. Comparator:		Non-antibiotic	preventive	intervention,	different	antibiotic,	placebo,	or	no	
treatment.	
iv. Outcomes:		Critical	outcomes	will	include	i)	incidence	of	incidence	of	IMI	during	the	dry-
cow	period	immediately	following	the	intervention,	ii)	incidence	of	IMI	during	the	first	30	
days	of	the	subsequent	lactation	and	iii)	incidence	of	clinical	mastitis	during	the	first	30	
days	of	the	subsequent	lactation.		Secondary	outcomes	will	include	total	antibiotic	use	
during	the	first	30	days	of	the	subsequent	lactation,	milk	production	during	the	
subsequent	lactation,	somatic	cell	count	during	the	first	test	of	the	subsequent	lactation	
or	the	average	of	the	first	3	tests	of	the	subsequent	lactation,	and	the	risk	of	culling	due	
to	mastitis	during	the	subsequent	lactation.	
2. At	the	group	level:	What	is	the	efficacy	of	antibiotic	treatment	of	all	quarters	of	all	cows	in	
a	group	at	dry-off	compared	to	selective	dry-cow	treatment?	
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i. Population:	Groups	of	dairy	cows	at	cessation	of	milking	after	their	first	(or	greater)	
lactation.		
ii. Intervention:	Blanket	dry-cow	treatment	with	an	antibiotic-containing	product.	
iii. Comparator:		Selective	dry-cow	treatment	regime.	
iv. Outcomes:		Critical	outcomes	will	include	incidence	of	clinical	mastitis	during	the	first	30	
days	of	the	subsequent	lactation,	and	reduction	in	new	or	existing	IMI	during	the	dry-cow	
period	or	during	the	first	30	days	of	lactation.		Secondary	outcomes	will	include	total	
antibiotic	use,	milk	production,	somatic	cell	count,	and	the	risk	of	culling	due	to	mastitis	
during	the	subsequent	lactation,	as	defined	at	the	individual-level,	but	amalgamated	at	
the	group	level.	
	
Methods	
	
Eligibility	criteria:		In	addition	to	eligibility	criteria	as	described	in	the	PICO	elements	described	
above,	eligibility	criteria	will	include	publication	in	English.		Both	published	and	non-published	
(grey	literature)	studies	are	eligible,	provided	they	report	the	results	of	a	primary	research	
study	with	a	concurrent	comparison	group	using	an	eligible	study	design.			
	
Study	designs	eligible:		Controlled	trials	with	natural	disease	exposure	will	be	eligible.		During	
full-text	eligibility	screening,	we	will	identify	studies	that	appear	to	address	the	review	
questions	but	using	an	observational	design	or	an	experimental	design	with	deliberate	disease	
induction;	however,	these	studies	will	not	be	included	in	further	steps	of	the	review.			
	
Information	sources:			
	
We	will	conduct	the	literature	search	in	a	range	of	relevant	bibliographic	databases	and	other	
information	sources	containing	both	published	and	unpublished	literature.	Table	1	presents	the	
resources	to	be	searched.		
	
Table	1:		Databases	and	information	sources	to	be	searched	
	
Database	/	information	source	 Interface	/	URL	
MEDLINE,	 MEDLINE	 In-Process	 and	
MEDLINE(R)	Daily	Epub	Ahead	of	Print	
Ovid	SP	
CAB	Abstracts		 CAB	Interface	
Science	Citation	Index		 Web	of	Science	
Conference	 Proceedings	 Citation	 Index	 –	
Science	
Web	of	Science	
Agricola	 Proquest	
	
We	will	also	hand-search	the	table	of	contents	of	the	following	relevant	conferences	from	1997	
to	2018:	
• Proceedings	of	the	American	Association	of	Bovine	Practitioners;	
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• 	World	Association	for	Buiatrics;	
• 	National	Mastitis	Council	Proceedings	
The FDA website containing the Freedom of Information New Animal Drug Approvals (NADA) 
summaries also will be searched.   
	
Search	strategy:			
	
A	Science	Citation	Index	(Web	of	Science)	search	strategy	designed	to	identify	studies	of	
antibiotic	treatments	during	the	dry-off	period	in	dairy	cattle	is	presented	in	Table	2.	The	search	
strategy	employs	a	multi-stranded	approach	to	maximize	sensitivity.		The	conceptual	structure	
is	as	follows:	
	
•	 Dairy	cows	AND	dry	off	AND	antibiotics;		
OR	
•	 Dry	cow	AND	antibiotics;		
OR	
• A	 precise	 search	 for	 dry	 cow	 therapy,	 management,	 interventions,	 strategies	 or	
treatments	in	order	to	retrieve	any	records	missed	by	the	two	combinations	above.		
	
Table	2:	Search	strategy	to	identify	studies	of	antibiotic	treatments	during	the	dry-off	period	
in	dairy	cattle	in	Science	Citation	Index	(Web	of	Science)	
	
#	14	 #13	OR	#12	 893	
#	13	 TS=(("dry	cow"	OR	"dry	cows")	NEAR/3	(therap*	OR	manag*	OR	intervention*	OR	treat*	
OR	strateg*))	 411	
#	12	 #11	AND	#7	 712	
#	11	 #10	OR	#9	OR	#8	 593,401	
#	10	 TS=("albamycin"	OR	"amoxicillin"	OR	"amoxycillin"	OR	"ampicillin"	OR	"benzathine"	OR	
"cathomycin"	OR	"cefalexin"	OR	"cefapirin"	OR	"cefalonium"	OR	"cefquinome"	OR	"ceftiofur"	
OR	"cephalexin"	OR	"cephapirin"	OR	"cephalonium"	OR	"cephapirin"	OR	"chlortetracycline"	OR	
"cloxacillin"	 OR	 "CTC"	 OR	 "danofloxacin"	 OR	 "dicloxacillin"	 OR	 "dihydrostreptomycin"	 OR	
"enrofloxacin"	 OR	 "erythromycin"	 OR	 "florfenicol"	 OR	 "framycetin"	 OR	 "gamithromycin"	 OR	
"gentamicin"	 OR	 "gentamycin"	 OR	 "lincomycin"	 OR	 lincosamide*	 OR	 "neomycin"	 OR	
"novobiocin"	 OR	 "oxytetracycline"	 OR	 "penethamate"	 OR	 "penicillin"	 OR	 "pirlimycin"	 OR	
"piroline"	 OR	 "spectinomycin"	 OR	 "sulfadimethoxine"	 OR	 "sulfafurazole"	 OR	
"sulfamethoxazole"	 OR	 "sulfisoxazole"	 OR	 "sulphadimethoxine"	 OR	 "tetracycline"	 OR	
"tildipirosin"	 OR	 "tilmicosin"	 OR	 "trimethoprim"	 OR	 "tulathromycin"	 OR	 "tylosin")
	 147,813	
#	9	 TS=(antimicrobial*	 OR	 "anti-microbial*"	 OR	 antibiotic*	 OR	 "anti-biotic*"	 OR	
antibacterial*	 OR	 "anti-bacterial*"	 OR	 antiinfect*	 OR	 anti-infect*	 OR	 bacteriocid*	 OR	
bactericid*	OR	microbicid*	OR	"anti-mycobacteri*"	OR	antimycobacteri*)	507,630	
#	8	 TS=("SDCT"	OR	"BDCT")	 140	
#	7	 #6	OR	#5	 9,647	
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#	6	 TS=("dry	cow"	OR	"dry	cows")	 1,186	
#	5	 #4	AND	#3	 8,965	
#	4	 TS=("drying	off"	OR	"dry	off"	OR	"dried	off"	OR	"dry	up"	OR	"drying	up"	OR	"dried	up"	
OR	 "drying	 period*"	OR	 "dry	 period*"	OR	 "dry	 udder*"	OR	 "dry	 teat*"	OR	 "pre-partum"	OR	
"prepartum"	OR	(("end"	OR	finish*	OR	stop*	OR	ceas*)	NEAR/3	lactat*)	OR	nonlactat*	OR	"non-
lactat*"	 OR	 postlactat*	 OR	 "post-lactat*"	 OR	 postmilk*	 OR	 "post-milk*"	 OR	 "involution"	 OR	
"steady	state")	 236,415	
#	3	 #2	OR	#1	 486,431	
#	2	 TS=(ayrshire*	OR	"brown	swiss*"	OR	"busa"	OR	"busas"	OR	canadienne*	OR	dexter*	OR	
"dutch	belted*"	OR	"estonian	red*"	OR	fleckvieh*	OR	friesian*	OR	girolando*	OR	guernsey*	OR	
holstein*	 OR	 illawarra*	 OR	 "irish	 moiled*"	 OR	 jersey*	 OR	 "meuse	 rhine	 issel*"	 OR	
montbeliarde*	 OR	 normande*	 OR	 "norwegian	 red*"	 OR	 "red	 poll"	 OR	 "red	 polls"	 OR	
shorthorn*	OR	"short	horn*")	 53,889	
#	1	 TS=("cow"	OR	"cows"	OR	"cattle"	OR	heifer*	OR	"dairy"	OR	"milking"	OR	"bovine"	OR	
"bovinae"	OR	buiatric*)	 460,464	
	
The	search	strategies	will	not	be	limited	by	date,	language,	or	publication	type.			
	
We	will	 conduct	 searches	using	each	database	 listed	 in	 the	protocol,	 translating	 the	 strategy	
appropriately	to	reflect	the	differences	in	database	interfaces	and	functionality.			
	
Study	records:	
	
			 Data	management:		We	will	download	the	results	of	searches	in	a	tagged	format	and	load	
them	into	bibliographic	software	(EndNote).	The	results	will	be	de-duplicated	using	several	
algorithms.		We	will	save	results	from	resources	that	do	not	allow	export	in	a	format	
compatible	with	EndNote	in	Word	or	Excel	documents	as	appropriate	and	manually	de-
duplicate.		The	de-duplicated	search	results	will	be	uploaded	into	online	systematic	review	
software	(DistillerSR®,	Ottawa,	ON,	Canada).	Reviewers	will	have	training	in	epidemiology	and	
in	systematic	review	methods.		Prior	to	both	abstract	and	full-text	screenings,	data	extraction,	
and	risk	of	bias	assessment,	the	reviewers	assigned	to	each	step	will	undergo	training	to	ensure	
consistent	data	collection	using	the	forms	created	in	DistillerSR®.		
	
				Selection	process:			In	the	first	round	of	screening,	abstracts	and	titles	will	be	screened	for	
eligibility.	Two	reviewers	will	independently	evaluate	each	citation	for	relevance	using	the	
following	questions:	
1)	Does	the	study	involve	antibiotic-containing	dry	cow	treatments	in	dairy	cattle	at	the	
individual	level	or	an	evaluation	of	group-level	strategies	for	administering	antibiotic-
containing	dry	cow	treatments	(such	as	selective	treatment	versus	blanket	treatment)?	
YES	(neutral	response),	NO	(EXCLUDE),	UNCLEAR	(neutral	response)	
2) Is	there	a	concurrent	comparison	group?	(i.e.	controlled	trial	with	natural	or	deliberate	
disease	exposure	or	analytical	observational	study)?	
YES	(neutral	response),	NO	(EXCLUDE),	UNCLEAR	(neutral	response)	
3) Is	the	full	text	available	in	English?	
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YES	(include	for	full	text	screening),	NO	(EXCLUDE),	UNCLEAR	(include	for	full	text	
screening)	
	
Citations	will	be	excluded	if	both	reviewers	responded	“no”	to	any	of	the	questions.		Any	
disagreements	will	be	resolved	by	consensus.		If	consensus	cannot	be	reached,	the	article	will	
be	marked	as	“unclear”	and	will	advance	to	full	text	screening.		A	pre-test	will	be	conducted	by	
all	reviewers	on	the	first	250	abstracts	to	ensure	clarify	of	questions	and	consistency	of	
understanding	of	the	questions.	
Following	title/abstract	screening,	eligibility	will	be	assessed	through	full-text	screening.		The	
same	questions	will	be	used	as	for	the	title	/	abstract	screening.	Two	reviewers	will	
independently	evaluate	the	full	text	articles,	with	any	disagreements	resolved	by	consensus.	If	
consensus	cannot	be	reached,	a	third	reviewer	will	be	used.	
			Data	collection	process:		Data	will	be	extracted	by	two	reviewers	working	independently.		Any	
disagreements	will	be	resolved	by	consensus	or,	if	consensus	cannot	be	reached,	a	third	
reviewer	will	be	used.		Authors	will	not	be	contacted	to	request	missing	data	or	to	clarify	
published	results.		A	form	for	data	extraction	will	be	created	for	this	review	in	DistillerSR®	and	
pre-tested	on	4	full	text	articles	to	ensure	question	clarity.	
	
Data	items:		
	
Study	level	data	to	be	extracted	include:	
• Study	design:	experimental	with	natural	disease	exposure,	experimental	with	deliberate	
disease	exposure	(“challenge	trial”),	or	analytical	observational	
• Country	
• Commercial	versus	research	trials	
• Year	the	study	was	collected	
• Months	of	data	collection	
• Breed	of	cattle	
• Lactation	number	(mean	for	entire	group	or	mean	by	group	if	provided)	
• Definition	of	intervention:	
o Antibiotic(s)	 used,	 route	 of	 administration,	 frequency	 of	 administration,	 dose,	
any	concurrent	treatments,		
o In	 addition,	 for	 the	 group	 level	 review	 question,	 details	 on	 the	 definition	 of	
selective	dry	cow	therapy.	
• Unit	of	allocation	(Cluster	(pen)	or	individual)		
• Description	of	comparison	group	
	
The	 above	 data	 will	 be	 collect	 for	 all	 of	 the	 primary	 hypothesis-testing	 studies	 that	 are	
identified	 as	 relevant	 at	 full	 text	 screening	 (i.e.,	 experimental	 studies	 with	 natural	 disease	
exposure,	experimental	studies	with	deliberate	disease	induction,	and	analytical	observational	
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studies).	 	The	arm	level	data,	described	below,	will	be	extracted	only	for	experimental	studies	
with	natural	disease	exposure.	
	
Arm	level	data	collected:	
• Number	of	animals	enrolled	
• Number	of	animals	lost	to	follow	up	
• Number	of	animals	analyzed	
• Any	 additional	 concurrent	 treatments	 –	 studies	 with	 additional	 treatments	 will	 be	
considered	 as	 separate	 treatments	 arms	 to	 studies	 with	 only	 an	 antibiotic-containing	
dry	cow	product.	
	
Outcomes	and	prioritization:			
	
Critical	outcomes	(in	order	of	prioritization):	
- Incidence	of	clinical	mastitis	during	the	first	30	days	of	the	subsequent	lactation	
- Reduction	in	new	IMI	during	the	dry-cow	period	(individual	level)	or	new	and	existing	
IMI	during	the	dry-cow	period	(group	level).	
- Reduction	of	new	IMI	during	the	first	30	days	of	lactation	(individual	level)	or	new	and	
existing	IMI	during	the	dry-cow	period	(group	level).	
			
Secondary	outcomes	(in	order	of	prioritization):	
- Total	antibiotic	use	to	treat	clinical	mastitis	during	the	first	30	days	of	the	subsequent	
lactation.	
- Milk	production	during	the	subsequent	lactation	
- Somatic	cell	count	the	first	test	of	the	subsequent	lactation,	or	the	average	of	the	first	3	
tests	of	the	subsequent	lactation.		
- Risk	of	culling	due	to	mastitis	during	the	subsequent	lactation.	
These	outcomes	were	prioritized	based	on	their	impact	on	animal	health	and	welfare	and	their	
economic	importance.		Formal	evaluation	of	these	criteria	for	prioritization	was	not	
undertaken.	
	
Data	will	be	collected	to	describe	the	outcomes	that	were	evaluated	for	all	eligible	studies,	
regardless	of	study	design.		The	specific	outcome	data,	as	described	below,	will	be	extracted	
only	for	experimental	studies	with	natural	disease	exposure.	
	
Outcome	data	to	be	collected:	
1) Incidence	of	clinical	mastitis	during	the	subsequent	lactation	
a. Case	definition	of	clinical	mastitis	
b. Level	at	which	outcome	data	were	measured	(quarter,	composite	individual,	
group)	
	
2) Outcomes	related	to	IMI	
a. Method	of	determining	the	study	subjects	were	free	of	IMI	at	dry-off	(individual	
level	review	question):	
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i. Negative	culture	at	dry	off	(extract	data	on	quarter	or	composite)	
ii. Somatic	cell	count	below	a	threshold	(extract	data	on	threshold	and	time	
period	for	assessment)	
iii. No	clinical	case	of	mastitis	during	specified	duration	(extract	data	on	
duration)	
iv. Other	(specify)	
v. Not	assessed	–	excluded	from	meta-analysis,	as	cannot	distinguish	
incident	from	prevalent	cases.		
b. Level	at	which	the	outcomes	were	measured	(quarter,	composite	individual,	
group)	
c. Method	of	diagnosis	of	IMI	status:	
i. Number	of	milk	samples	used	to	classify	IMI	status	and	timing	of	
sampling	for	cultures		
ii. Whether	National	Mastitis	Council	(NMC)	Laboratory	Methods	were	
stated	as	used			
iii. If	other	methods	were	used	in	parallel	or	exclusively	e.g.	PCR;	Petrifilm	or	
selective	media	
d. Type	of	bacteria:	
i. Individual	bacteria	results	will	be	extracted	for:	Coliforms,	Strep.	uberis,	
Strep.	agalactica,	Staph.	aureus	
ii. Grouped	bacteria	results	will	be	extracted	for:	Major	contagious	mastitis	
pathogens	(Staph.	aureus	and	Strep.	agalactia),	and	Major	environmental	
mastitis	pathogens	(Strep.	uberis	and	coliforms)	
	
For	each	of	the	primary	and	secondary	outcomes,	we	will	extract	the	possible	metrics	in	the	
following	order:		
• 1st	priority:	Adjusted	summary	effect	size	(adjusted	risk	ratio	or	adjusted	odds	ratio,	mean	
differences	for	continuous	outcomes)	and	variables	included	in	adjustment	and	
corresponding	precision	estimate.		
• 2nd	priority:	Unadjusted	summary	effect	size				
• 3rd	priority:	Arm	level	risk	of	the	outcome,	or	arm	level	mean	of	the	outcome	
(continuous	outcomes)	
• For	cluster-randomized	designs,	the	approach	to	the	analysis	of	non-independent	
observations	i.e.,	not	reported,	‘multilevel	model,'	a	‘variance	components	analysis'	or	
may	use	‘generalized	estimating	equations	(GEEs),'	among	other	techniques.			
• Variance	components	
	
If	variance	estimates	are	not	reported,	but	the	authors	provide	the	data	necessary	to	calculate	
them	using	standard	formulas,	we	will	calculate	these	data.		If	results	are	provided	only	in	
graphical	form,	we	will	estimate	the	numerical	results	using	WebPlotDigitizer	
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(https://automeris.io/WebPlotDigitizer/),	if	the	full	text	is	in	a	suitable	format	for	using	this	
resource.	
	
Risk	of	bias	in	individual	studies:		Risk	of	bias	will	only	be	assessed	for	controlled	trials	with	
natural	disease	exposure.		Risk	of	bias	assessment	will	be	performed	at	the	outcome	level	for	
each	of	the	critical	outcomes	using	the	Cochrane	risk	of	bias	instrument	(Higgins	et	all,	2016),	
with	the	signaling	questions	modified	as	necessary	for	the	specific	review	question.	The	ROB-
2.0	for	clustered	–RCT	and	individual	RCTs	will	be	used	depending	upon	the	study	design.		
These	tools	are	available	at	https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool.	
	
Data	synthesis:		
	
Network	meta-analysis.	Network	meta-analysis	(aka	mixed	treatment	comparison	meta-
analysis)	will	be	conducted	for	each	of	the	primary	outcomes	and	separately	for	the	individual	
level	and	group	level	questions,	as	the	group	level	question	by	necessity	combines	incident	and	
prevalent	IMI.		Network	meta-analysis	will	use	the	approach	described	by	NICE	Decision	
Support	Unit	technical	document	(Dias	et	al.,	2014;	O’Connor	et	al.,	2013,	O’Connor	et	al.,	
2016).	The	approach	to	reporting	will	use	the	PRISMA-	NMA	(http://www.prisma-
statement.org/Extensions/NetworkMetaAnalysis.aspx).		Planned	a	priori	sub-group	analyses	
will	be	conducted	for	randomized	versus	non-randomized	trials	and,	for	the	group	level	review	
question,	by	method	of	selecting	the	cows	for	treatment.	
	
Meta-bias(es):		Small	study	effects	(“publication	bias”)	will	be	assessed	for	all	antibiotic-
comparator	combinations	where	there	are	at	least	10	studies	in	the	meta-analysis.	If	feasible,	
we	will	use	approaches	to	assessing	publication	bias	in	the	network	of	evidence	using	
previously	proposed	approaches	(Mavridis	et	al.,	2013;	Mavridis	et	al.,	2014).		
Confidence	 in	cumulative	evidence:	 	The	quality	of	evidence	for	each	critical	outcome	will	be	
assessed	using	the	approach	proposed	by	GRADE	(GRADE,	2015,	Puhan	et	al.,	2014),	while	also	
considering	the	nature	of	the	network	meta-analysis	(Jansen	et	al.,	2011).	
Discussion:		
	
This	systematic	review	will	provide	a	synthesis	of	the	current	evidence	regarding	the	efficacy	of	
antibiotic-containing	dry	cow	treatments	at	the	individual	level	for	preventing	mastitis	and	
treatment	strategies	at	the	group	level	for	preventing	and	treating	mastitis	during	the	dry	cow	
period	and	early	lactation.		Results	will	be	helpful	for	veterinarians	and	dairy	producers	when	
making	evidence-informed	decisions	regarding	the	use	of	antibiotic-containing	dry	cow	
treatment.		The	results	also	will	be	helpful	for	identifying	specific	gaps	in	knowledge	related	to	
the	efficacy	of	these	products	for	targeting	additional	research.	
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